Dianthus Therapeutics Stock (NASDAQ:DNTH)

Forecast Revenue Ownership Financials Chart

Previous Close

$27.98

52W Range

$0.68 - $33.77

50D Avg

$27.87

200D Avg

$22.23

Market Cap

$781.41M

Avg Vol (3M)

$274.89K

Beta

-

Div Yield

-

DNTH Company Profile

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

53

IPO Date

Jun 21, 2018

Website

DNTH Performance

DNTH Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	-	$6.42M	$1.48M
Operating Income	$-48.17M	$-29.70M	$-13.09M
Net Income	$-43.55M	$-28.48M	$-13.11M
EBITDA	$-48.17M	$-29.69M	$-13.06M
Basic EPS	-	$-1.92	$-0.88
Diluted EPS	-	$-1.92	$-0.88

Fiscal year ends in Dec 23 | Currency in USD